Ligand Pharmaceuticals Incorporated (LGND) is a leading biotechnology business based in the US. It opened the day at USD$135.85 after a previous close of USD$135.93. During the day the price has varied from a low of USD$133.13 to a high of USD$135.85. The latest price was USD$133.25 (25 minute delay). Ligand Pharmaceuticals is listed on the NASDAQ and employs 155 staff. All prices are listed in US Dollars.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Since the stock market crash in March caused by coronavirus, Ligand Pharmaceuticals's stock price has had significant positive movement.
Its last market close was $131.4, which is 23.34% up on its pre-crash value of $100.73 and 129.56% up on the lowest point reached during the March crash when the stocks fell as low as $57.24.
If you had bought $1,000 worth of Ligand Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $787.93 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,467.74.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|52-week range||$78.26 - $219.75|
|50-day moving average||$133.96|
|200-day moving average||$128.99|
|Wall St. target price||$207.86|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$2.89|
|1 week (2021-10-13)||3.52%|
|1 month (2021-09-20)||-2.52%|
|3 months (2021-07-21)||7.33%|
|6 months (2021-04-21)||-12.39%|
|1 year (2020-10-21)||65.43%|
|2 years (2019-10-21)||22.73%|
|3 years (2018-10-19)||187.52|
|5 years (2016-10-21)||42.50%|
Valuing Ligand Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ligand Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ligand Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 45x. In other words, Ligand Pharmaceuticals shares trade at around 45x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Ligand Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.954. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ligand Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Ligand Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $77.6 million.
The EBITDA is a measure of a Ligand Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$251.7 million|
|Operating margin TTM||13.87%|
|Gross profit TTM||$96.6 million|
|Return on assets TTM||1.75%|
|Return on equity TTM||6.47%|
|Market capitalisation||$2.2 billion|
TTM: trailing 12 months
There are currently 1.7 million Ligand Pharmaceuticals shares held short by investors – that's known as Ligand Pharmaceuticals's "short interest". This figure is 2.4% down from 1.8 million last month.
There are a few different ways that this level of interest in shorting Ligand Pharmaceuticals shares can be evaluated.
Ligand Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ligand Pharmaceuticals shares currently shorted divided by the average quantity of Ligand Pharmaceuticals shares traded daily (recently around 351800.40567951). Ligand Pharmaceuticals's SIR currently stands at 4.93. In other words for every 100,000 Ligand Pharmaceuticals shares traded daily on the market, roughly 4930 shares are currently held short.
However Ligand Pharmaceuticals's short interest can also be evaluated against the total number of Ligand Pharmaceuticals shares, or, against the total number of tradable Ligand Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ligand Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Ligand Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1093% of the tradable shares (for every 100,000 tradable Ligand Pharmaceuticals shares, roughly 109 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ligand Pharmaceuticals.
We're not expecting Ligand Pharmaceuticals to pay a dividend over the next 12 months.
Ligand Pharmaceuticals's shares were split on a 1:6 basis on 18 November 2010. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ligand Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Ligand Pharmaceuticals shares which in turn could have impacted Ligand Pharmaceuticals's share price.
Over the last 12 months, Ligand Pharmaceuticals's shares have ranged in value from as little as $78.26 up to $219.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ligand Pharmaceuticals's is 1.0878. This would suggest that Ligand Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in Emeryville, California. .
Steps to owning and managing Bucket Studio shares from South Africa.
Learn how to stake AVAX tokens and earn rewards by supporting the Avalanche blockchain.
True to its name, SuperRare is an NFT marketplace that focuses on crypto art tokenised on the Ethereum blockchain. The result is part marketplace and part social network for the artistic side of the NFT community.
Steps to owning and managing Evergrande shares from South Africa.
This guide will show you step-by-step instructions on how to buy the Bitcoin Gold (BTG) token as well as a list of exchanges you can trade it on.
Buy and sell unique digital assets on the largest NFT marketplace in the crypto space.
This guide will show you step-by-step instructions on how to buy the Smooth Love Potion (SLP) token as well as a list of exchanges you can trade it on.
If you are looking to start buying, selling and trading NFTs, Mintable is one of the best places to start.
Sorare is an NFT-based fantasy football platform where players can earn money.
This guide will show you step-by-step instructions on how to buy the MimbleWimbleCoin (MWC) token as well as a list of exchanges you can trade it on.
finder.com.au is one of Australia's leading comparison websites. We compare from a wide set of banks, insurers and product issuers. We value our editorial independence and follow editorial guidelines.
finder has access to track details from the product issuers listed on our sites. Although we provide information on the products offered by a wide range of issuers, we don't cover every available product or service.
Please note that the information published on our site should not be construed as personal advice and does not consider your personal needs and circumstances. While our site will provide you with factual information and general advice to help you make better decisions, it isn't a substitute for professional advice. You should consider whether the products or services featured on our site are appropriate for your needs. If you're unsure about anything, seek professional advice before you apply for any product or commit to any plan.
Products marked as 'Promoted' or 'Advertisement' are prominently displayed either as a result of a commercial advertising arrangement or to highlight a particular product, provider or feature. Finder may receive remuneration from the Provider if you click on the related link, purchase or enquire about the product. Finder's decision to show a 'promoted' product is neither a recommendation that the product is appropriate for you nor an indication that the product is the best in its category. We encourage you to use the tools and information we provide to compare your options.
Where our site links to particular products or displays 'Go to site' buttons, we may receive a commission, referral fee or payment when you click on those buttons or apply for a product.
When products are grouped in a table or list, the order in which they are initially sorted may be influenced by a range of factors including price, fees and discounts; commercial partnerships; product features; and brand popularity. We provide tools so you can sort and filter these lists to highlight features that matter to you.
We try to take an open and transparent approach and provide a broad-based comparison service. However, you should be aware that while we are an independently owned service, our comparison service does not include all providers or all products available in the market.
Some product issuers may provide products or offer services through multiple brands, associated companies or different labelling arrangements. This can make it difficult for consumers to compare alternatives or identify the companies behind the products. However, we aim to provide information to enable consumers to understand these issues.
Providing or obtaining an estimated insurance quote through us does not guarantee you can get the insurance. Acceptance by insurance companies is based on things like occupation, health and lifestyle. By providing you with the ability to apply for a credit card or loan, we are not guaranteeing that your application will be approved. Your application for credit products is subject to the Provider's terms and conditions as well as their application and lending criteria.